Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of setmelanotide in genetic obesity due to MC4R-pathway variants
NL-OMON53452Phase 3Recruiting
- Sponsor
- IQVIA Biotech
- Start
- Dec 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in No canonical full name exists for "genetic obesity." and obesity comparing Setmelanotide with Placebo (2 arms). Primary endpoint: Change in body weight. Started Dec 2022; status: recruiting.
02
Drugs
setmelanotide
03
Conditions
No canonical full name exists for "genetic obesity."obesity
Beyond the preview
Go deeper on NL-OMON53452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53452.